Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study

Vincenzo La Bella, Giuseppe Lauria, Irene Tramacere, Gianni Sorarù, Paolo Volanti, Eleonora Dalla Bella, Romana Rizzi, Giovanni Antonini, Eleonora Dalla Bella, Enrico Granieri, Massimiliano Filosto, Maria Rosaria Monsurrò, Massimiliano Filosto, Raffaella Fazio, Gianni Sorarù, Jessica Mandrioli, Giuseppe Borghero, Claudia Caponnetto, Roberto Eleopra, Margherita CapassoRocco Quatrale, Letizia Mazzini, Vladimiro Pietrini, Raffaella Fazio, Giancarlo Logroscino, Gabriele Siciliano, Graziella Filippini, Adriano Chiò, Massimo Corbo, Fabrizio Salvi, Gabriele Mora, Fabio Giannini, Paolo Volanti

Risultato della ricerca: Articlepeer review

24 Citazioni (Scopus)


Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italiancentres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-generated by blocks, stratified by centre, disease severity (ALSFRS-R cut-off score of 33) and onset (spinal or bulbar). The main outcome analysis was performed in all randomised patients and by intentionto-treat for the entire population and patients stratified by severity and onset. The study is registered, EudraCT 2009-016066-91. Results We randomly assigned 208 patients, of whom 5 (1 rhEPO and 4 placebo) withdrew consent and 3 ( placebo) became ineligible (retinal thrombosis, respiratory insufficiency, SOD1 mutation) before receiving treatment; 103 receiving rhEPO and 97 placebo were eligible for analysis. At 12 months, the annualised rate of death (rhEPO 0.11, 95% CI 0.06 to 0.20; placebo: 0.08, CI 0.04 to 0.17), tracheotomy or >23 h NIV (rhEPO 0.16, CI 0.10 to 0.27; placebo 0.18, CI 0.11 to 0.30) did not differ between groups, also after stratification by onset and ALSFRS-R at baseline. Withdrawal due to AE was 16.5% in rhEPO and 8.3% in placebo. No differences were found for secondary outcomes. Conclusions RhEPO 40 000 IU fortnightly did not change the course of ALS.
Lingua originaleEnglish
pagine (da-a)879-886
Numero di pagine8
RivistaJournal of Neurology, Neurosurgery and Psychiatry
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2746???
  • ???subjectarea.asjc.2700.2728???
  • ???subjectarea.asjc.2700.2738???


Entra nei temi di ricerca di 'Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study'. Insieme formano una fingerprint unica.

Cita questo